Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MRGPRX1 | Q96LB2 | 6/20 | 0.44 |
| ▸ | HRH1 | P35367 | 1/20 | 0.44 |
| ▸ | BRAF | P15056 | 4/20 | 0.42 |
| ▸ | TLR4 | O00206 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | MAP2K2 | P36507 | 4/20 | 0.36 |
| ▸ | MAP2K1 | Q02750 | 4/20 | 0.36 |
| ▸ | KIT | P10721 | 1/20 | 0.36 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.36 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.36 |
| ▸ | TSPO | P30536 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19050669 | 0.95 | MRGPRX1 (0.40) | MRGPRX1HRH1BRAFTLR4MEN1 | |
| SCHEMBL19050673 | 0.94 | MRGPRX1 (0.40) | MRGPRX1HRH1BRAFTLR4MEN1 | |
| SCHEMBL19049852 | 0.92 | MRGPRX1 (0.39) | MRGPRX1HRH1BRAFTLR4MEN1 | |
| SCHEMBL19050657 | 0.91 | MEN1 (0.47) | MRGPRX1HRH1BRAFTLR4MEN1 | |
| SCHEMBL19050690 | 0.88 | MRGPRX1 (0.41) | MRGPRX1HRH1BRAFTLR4MEN1 | |
| SCHEMBL387927 | 0.87 | MAP2K1 (0.44) | MRGPRX1BRAFTLR4KMT2AMAP2K2 | |
| SCHEMBL14263851 | 0.85 | MAP2K2 (0.40) | MEN1KMT2AMAPK1MAP2K2MAP2K1 | |
| SCHEMBL12407095 | 0.85 | MRGPRX1 (0.51) | MRGPRX1HRH1BRAFTLR4KMT2A | |
| SCHEMBL13672516 | 0.85 | KIT (0.39) | MRGPRX1BRAFTLR4MAP2K2MAP2K1 | |
| SCHEMBL391574 | 0.85 | MAP2K1 (0.53) | BRAFMAP2K2MAP2K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130261120-A1 | SUBSTITUTED N-(2-ARYLAMINO)ARYL SULFONAMIDE-CONTAINING COMBINATIONS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-10-03 | — | — | US | claimed |
| EP-2621486-A1 | SUBSTITUTED N-(2-ARYLAMINO)ARYL SULFONAMIDE-CONTAINING COMBINATIONS | Bayer Intellectual Property GmbH (DE) | 2013-08-07 | — | — | EP | claimed |
| US-20130184270-A1 | SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE-CONTAINING COMBINATIONS | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2013-07-18 | — | — | US | claimed |
| EP-2558126-A2 | SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE-CONTAINING COMBINATIONS | Bayer Intellectual Property GmbH (DE) | 2013-02-20 | — | — | EP | claimed |
| WO-2012041987-A1 | SUBSTITUTED N-(2-ARYLAMINO)ARYL SULFONAMIDE-CONTAINING COMBINATIONS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2012-04-05 | — | — | WO | claimed |
| WO-2011128407-A2 | SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE-CONTAINING COMBINATIONS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2011-10-20 | — | — | WO | claimed |
| US-20170183333-A1 | DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES AS INHIBITORS OF MEK | ARDEA BIOSCIENCES, INC. (US) | 2017-06-29 | — | — | US | disclosed |
| US-20170183333-A1 | DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES AS INHIBITORS OF MEK | ARDEA BIOSCIENCES, INC. (US) | 2017-06-29 | — | — | US | disclosed |
| US-9381177-B2 | Substituted N-(2-arylamino)aryl sulfonamide-containing combinations | BAYER INTELLECTUAL PROPERTY GMBH (DE) | 2016-07-05 | — | — | US | disclosed |
| US-20140378466-A1 | DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES AS INHIBITORS OF MEK | ARDEA BIOSCIENCES (US) | 2014-12-25 | — | — | US | disclosed |
| US-20140378466-A1 | DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES AS INHIBITORS OF MEK | ARDEA BIOSCIENCES (US) | 2014-12-25 | — | — | US | disclosed |
| US-8829052-B2 | Derivatives of N-(arylamino)sulfonamides as inhibitors of MEK | ARDEA BIOSCIENCES, INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-8829052-B2 | Derivatives of N-(arylamino)sulfonamides as inhibitors of MEK | ARDEA BIOSCIENCES, INC. (US) | 2014-09-09 | — | — | US | disclosed |
| US-7759518-B2 | (S)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide; MEK kinase (mitogen-activated ERK-activating kinases, MAP kinase kinase); cancer, tumors, autoimmune disorders, ischemia, rheumatoid arthritis, multiple sclerosis, psoriasis, restenosis | ARDEA BIOSCIENCES (US) | 2010-07-20 | — | — | US | disclosed |
| US-20090082457-A1 | (S)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide; MEK kinase (mitogen-activated ERK-activating kinases, MAP kinase kinase); cancer, tumors, autoimmune disorders, ischemia, rheumatoid arthritis, multiple sclerosis, psoriasis, restenosis | ANDREA BIOSCIENCES, INC. (US) | 2009-03-26 | — | — | US | disclosed |
| US-20090082457-A1 | (S)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide; MEK kinase (mitogen-activated ERK-activating kinases, MAP kinase kinase); cancer, tumors, autoimmune disorders, ischemia, rheumatoid arthritis, multiple sclerosis, psoriasis, restenosis | ANDREA BIOSCIENCES, INC. (US) | 2009-03-26 | — | — | US | disclosed |
| US-20090082457-A1 | (S)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide; MEK kinase (mitogen-activated ERK-activating kinases, MAP kinase kinase); cancer, tumors, autoimmune disorders, ischemia, rheumatoid arthritis, multiple sclerosis, psoriasis, restenosis | ANDREA BIOSCIENCES, INC. (US) | 2009-03-26 | — | — | US | disclosed |
| US-20080058340-A1 | MEK kinase (mitogen-activated ERK-activating kinases or MAP kinase kinase); cancer, tumors, infections, autoimmune disorders, stroke, ischemia, rheumatoid arthritis, multiple sclerosis, psoriasis, restenosis; 1-sulfonamido-2-(phenylamino)-4-fluorobenzene compounds | ARDEA BIOSCIENCES, INC. (US) | 2008-03-06 | — | — | US | disclosed |
| US-20080058340-A1 | MEK kinase (mitogen-activated ERK-activating kinases or MAP kinase kinase); cancer, tumors, infections, autoimmune disorders, stroke, ischemia, rheumatoid arthritis, multiple sclerosis, psoriasis, restenosis; 1-sulfonamido-2-(phenylamino)-4-fluorobenzene compounds | ARDEA BIOSCIENCES, INC. (US) | 2008-03-06 | — | — | US | disclosed |
| US-20080058340-A1 | MEK kinase (mitogen-activated ERK-activating kinases or MAP kinase kinase); cancer, tumors, infections, autoimmune disorders, stroke, ischemia, rheumatoid arthritis, multiple sclerosis, psoriasis, restenosis; 1-sulfonamido-2-(phenylamino)-4-fluorobenzene compounds | ARDEA BIOSCIENCES, INC. (US) | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058340-A1 | MEK kinase (mitogen-activated ERK-activating kinases or MAP kinase kinase); cancer, tumors, infections, autoimmune disorders, stroke, ischemia, rheumatoid arthritis, multiple sclerosis, psoriasis, restenosis; 1-sulfonamido-2-(phenylamino)-4-fluorobenzene compounds | BRAF, MAPK1, MAPK12 | MRGPRX1 420/4885HRH1 1722/4885BRAF 1/4885 |
| US-20170183333-A1 | DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES AS INHIBITORS OF MEK | BRAF, NRAS, MAP3K2 | MRGPRX1 1641/4885HRH1 1890/4885BRAF 1/4885 |
| US-20130184270-A1 | SUBSTITUTED 2,3-DIHYDROIMIDAZO[1,2-C]QUINAZOLINE-CONTAINING COMBINATIONS | KIT, CSNK2A1, CSNK1A1 | MRGPRX1 3185/4885HRH1 389/4885BRAF 23/4885 |
| US-20130261120-A1 | SUBSTITUTED N-(2-ARYLAMINO)ARYL SULFONAMIDE-CONTAINING COMBINATIONS | KIT, CHUK, IKBKB | MRGPRX1 3314/4885HRH1 1046/4885BRAF 43/4885 |
| US-20140378466-A1 | DERIVATIVES OF N-(ARYLAMINO) SULFONAMIDES AS INHIBITORS OF MEK | BRAF, NRAS, MAP3K2 | MRGPRX1 1641/4885HRH1 1890/4885BRAF 1/4885 |
| US-20090082457-A1 | (S)-N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide; MEK kinase (mitogen-activated ERK-activating kinases, MAP kinase kinase); cancer, tumors, autoimmune disorders, ischemia, rheumatoid arthritis, multiple sclerosis, psoriasis, restenosis | BRAF, MAPK1, MAP2K2 | MRGPRX1 796/4885HRH1 1533/4885BRAF 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.